EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic review

M H Comce, R A Weersink, U Beuers, R M van Hest iD, M A Lantinga

Journal of Antimicrobial Chemotherapy · 04.11.2024 · 79 (11) · 2750-2761

DOI: 10.1093/jac/dkae310 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 18.09.2024. Verfasst von M H Comce und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Anti-Bacterial Agents, Vancomycin, Meropenem. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Gastroenterology & Hepatology of the Amsterdam University Medical Center, Amsterdam, the Netherlands.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Patients with liver cirrhosis are prone to develop severe bacterial infections. Pharmacokinetics (PK) of antibiotics in cirrhosis are potentially affected by impaired biotransformation phases 0–3 and consequences of portal hypertension such as portovenous shunting, ascites formation and/or acute kidney injury (AKI). We aimed to elucidate to what extent PK of selected antibiotics and, therefore, dosage recommendations are affected in adults with cirrhosis.

Methods

We performed a systematic search in PubMed, Embase, Cochrane and CINAHL on effects of cirrhosis on PK profiles of ceftriaxone, fosfomycin, gentamicin, meropenem, nitrofurantoin, piperacillin/tazobactam and vancomycin in adults. Antibiotics were selected based on the lack of specific dosing recommendations for adults with cirrhosis. We included studies reporting on ≥1 of the following PK parameters: AUC, half-life (t½), CL, volume of distribution (Vd), peak (Cmax) or trough concentrations (Cmin).

Results

We identified 15 studies (ceftriaxone, n = 5; gentamicin, n = 3; meropenem n = 5; vancomycin, n = 2), including 379 patients with cirrhosis, of which two were of high quality. No eligible studies were identified for fosfomycin, nitrofurantoin or piperacillin/tazobactam. Ceftriaxone unbound concentration increased in cirrhosis, but was mitigated by increased renal CL. Gentamicin levels in ascitic fluid were comparable to those in plasma. Meropenem PK parameters were not altered in cirrhosis without AKI, but in the presence of AKI a decrease in CL was observed. In contrast, vancomycin CL decreased in advanced cirrhosis.

Conclusions

Available data in studies of mostly moderate quality suggest that PK of ceftriaxone, meropenem and vancomycin are altered in cirrhosis. More advanced PK studies are needed to provide specific dosing recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisAnti-Bacterial AgentsVancomycinMeropenemCeftriaxoneHumansGentamicinsBacterial InfectionsAdult

Substanzen

Anti-Bacterial AgentsVancomycinMeropenemCeftriaxoneGentamicins

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands.
  • Department of Clinical Pharmacy, Deventer Hospital, Deventer, The Netherlands.
  • Department of Pharmacy and Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection & Immunity, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands.
  • European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.

ORCID-Profile: R M van Hest

Förderung

  • Department of Gastroenterology & Hepatology of the Amsterdam University Medical Center, Amsterdam, the Netherlands

Zitieren

APA

Comce, M. H., Weersink, R. A., Beuers, U., van Hest, R. M., & Lantinga, M. A. (2024). Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic review. Journal of Antimicrobial Chemotherapy, 79(11), 2750-2761. https://doi.org/10.1093/jac/dkae310

Vancouver

Comce MH, Weersink RA, Beuers U, van Hest RM, Lantinga MA. Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic review. Journal of Antimicrobial Chemotherapy. 2024;79(11):2750-2761. doi:10.1093/jac/dkae310

BibTeX
@article{Comce2024,
  author = {Comce, M H and Weersink, R A and Beuers, U and van Hest, R M and Lantinga, M A},
  title = {Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic review},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {11},
  pages = {2750--2761},
  doi = {10.1093/jac/dkae310}
}
Kostenlos starten →